Transplant News and Research

RSS

Research shows anti-microbial medications lead to acute liver failure

New research shows that anti-microbial medications are a common cause of drug-induced liver injury (DILI) leading to acute liver failure (ALF), with women and minorities disproportionately affected.

1 Dec 2010

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Ikaria, Inc. announced that it has enrolled the first patients in its pivotal Phase III trial for LUCASSIN® (terlipressin). The multi-center, randomized, placebo-controlled, double-blind trial is known as the REVERSE Trial.

30 Nov 2010

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Cytheris SA, a clinical-stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the publication of a case study report based on successful treatment of Progressive Multifocal Leukoencephalopathy (PML) with combination therapy consisting of two investigational agents, Cytheris' recombinant human interleukin-7 (CYT107) and CMX001, an investigational, oral broad-spectrum antiviral drug (Chimerix, Research Triangle Park, NC) in the Journal of Antimicrobial Chemotherapy.

30 Nov 2010

Gen-Probe submits PMA to FDA for APTIMA HPV assay to detect cervical cancer

Gen-Probe Incorporated announced today that the Company has submitted a Premarket Approval Application (PMA) to the US Food and Drug Administration (FDA) for its APTIMA® HPV (human papillomavirus) assay, a new molecular test that detects high-risk HPV infections that are associated with cervical cancer and precancerous lesions.

30 Nov 2010

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Baylor Health Care System Foundation announces that Annette C. and Harold C. Simmons have pledged $20 million to benefit transplantation initiatives within Baylor Health Care System. In recognition of this transformational gift, Baylor will rename the institute the Annette C. and Harold C. Simmons Transplant Institute.

29 Nov 2010

Jefferson Hospital offers shortest wait times for patients seeking kidney transplant: SRTR

A recent listing of Philadelphia adult kidney transplant programs by The Scientific Registry of Transplant Recipients (SRTR) has listed the transplant program at Thomas Jefferson University Hospital as having the shortest wait times for patients seeking a transplant among programs that have a three-year survival rate of greater than 90 percent.

29 Nov 2010

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

A decade of refinements in marrow and stem cell transplantation to treat blood cancers significantly reduced the risk of treatment-related complications and death, according to an institutional self-analysis of transplant-patient outcomes conducted at Fred Hutchinson Cancer Research Center.

25 Nov 2010

Genzyme meets FDA consent decree by ending fill/finish activities in Allston plant

Genzyme Corporation announced today that the company has ended fill/finish operations within its Allston plant for products sold in the United States, as required by the FDA consent decree.

25 Nov 2010

Discovery may lead to new generation of drugs to minimize heart attack risk

An international team led by researchers from the Universities of Leicester and Cambridge has announced a breakthrough in identifying people at risk of developing potentially fatal blood clots that can lead to heart attack.

24 Nov 2010

Cord Blood America shares web site post on Thanksgiving Day

On this day before Thanksgiving, a day when our entire nation gives thanks for its blessing, Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells to families nationwide and internationally, would like to share with its investors a post from its web site by Dr. Geoffrey O'Neill, CBAI Vice President, Operations.

24 Nov 2010

Omni Bio receives U.S patent for treatment of viral infections

Omni Bio Pharmaceutical, Inc., today announced that U.S. Patent No.7,807,781, entitled "Inhibitors of Serine Protease Activity and Their Use in Methods and Compositions for Treatment of Viral Infections", was issued by the United States Patent and Trademark Office on October 5, 2010

23 Nov 2010

Racial disparities in risk and survival among children with neuroblastoma: Study

Black, Asian, and Native American children are more likely than white and Hispanic children to die after being treated for neuroblastoma, according to new research on the pediatric cancer. The study, of more than 3,500 patients with the disease, is the largest ever to look at racial disparities in risk and survival for the most common solid cancer found in young children.

23 Nov 2010

Genzyme issues Award of Excellence to Shanghai ChemPartner

ShangPharma Corporation a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, received an Award of Excellence from Genzyme.

23 Nov 2010

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced that data demonstrating preclinical efficacy of Chimerix's lead antiviral compound CMX001 against herpes simplex virus (HSV) as well as its ability to penetrate the blood-brain barrier was published in the November 15, 2010 issue of The Journal of Infectious Diseases.

23 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

On November 20 at the American Society of Nephrology 43rd Annual Meeting, Columbia University Assistant Professor of Clinical Medicine Andrew Bomback, MD, presented results from a patient case series assessing the potential therapeutic value of H.P. Acthar Gel (repository corticotropin injection) as a treatment for patients with nephrotic syndrome, a kidney disorder characterized by excessive loss of urinary protein.

22 Nov 2010

Racial and socioeconomic disparities exist in kidney transplantation

Research shows that people with low incomes are more likely to develop kidney failure and less likely to receive a living donor kidney transplant than people of other socioeconomic classes.

22 Nov 2010

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

Alexion Pharmaceuticals, Inc. announced today that a Phase 2 clinical study investigating Soliris (eculizumab) as a treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) who are resistant to plasma therapy met primary and key secondary endpoints with high levels of statistical and clinical significance, according to results presented today at the American Society of Nephrology (ASN) annual meeting in Denver.

21 Nov 2010

CBS Sports to feature CMC and LifeShare Of The Carolinas

Carolinas Medical Center (CMC) and its Organ Procurement partner, LifeShare Of The Carolinas, will be featured in a special CBS Sports broadcast airing on Thanksgiving Day, Nov. 25, during "NFL Today." The segment is expected to air between noon and 12:30 pm.

20 Nov 2010

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Among kidney disease patients, earlier care from a nephrologist is associated with a decreased likelihood of developing end-stage renal disease and a lower risk of death during the first year of dialysis, according to a study presented at the American Society of Nephrology's 43rd Annual Meeting and Scientific Exposition.

20 Nov 2010

Transplant News and Research

Research shows anti-microbial medications lead to acute liver failure

Ikaria initiates enrollment in LUCASSIN Phase III trial for HRS Type 1

Cytheris' combinational therapy demonstrates possible therapeutic strategy for PML

Gen-Probe submits PMA to FDA for APTIMA HPV assay to detect cervical cancer

Baylor Health Care System receives $20 million to benefit transplantation initiatives

Jefferson Hospital offers shortest wait times for patients seeking kidney transplant: SRTR

Collective efforts in transplantation reduces risk of treatment-related complications in blood cancer

Genzyme meets FDA consent decree by ending fill/finish activities in Allston plant

Discovery may lead to new generation of drugs to minimize heart attack risk

Cord Blood America shares web site post on Thanksgiving Day

Omni Bio receives U.S patent for treatment of viral infections

Racial disparities in risk and survival among children with neuroblastoma: Study

Genzyme issues Award of Excellence to Shanghai ChemPartner

Preclinical trial shows Chimerix’s CMX001 inhibits HSV replication

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Acthar Gel may be a viable treatment option for resistant nephrotic syndrome

Racial and socioeconomic disparities exist in kidney transplantation

Alexion's Soliris Phase 2 clinical study for aHUS meets primary, secondary endpoints

CBS Sports to feature CMC and LifeShare Of The Carolinas

Nephrologist’s care reduces ESRD development during first year of dialysis: Study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News